Atara Biotherapeutics, Inc. (ATRA) Stock

Atara Biotherapeutics, Inc. (ATRA) is a Healthcare stock trading at $9.77 (as of 2026-08-21), with a market capitalization of $98.07M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Atara Biotherapeutics, Inc. develops off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune, and viral diseases in the United States. Its clinical-stage programs include tabelecleucel for EBV-driven post-transplant lymphoproliferative disease and tumors, as well as next-generation CAR T therapies targeting mesothelin, B-cell malignancies, and additional indications such as multiple sclerosis and HPV-associated cancers.

Understand Atara Biotherapeutics, Inc.: how it makes money

Atara Biotherapeutics develops off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune, and viral diseases, and it makes money from commercialization revenue tied to treating patients and from license and collaboration revenue tied to partnering.

The core profit engine is converting its T-cell immunotherapy candidates into real-world monetization through patient treatments (commercialization revenue) and external partnering (license and collaboration revenue), while development progress largely determines the future ability to scale that engine.

Revenue by segment (latest quarter)
Commercial	$0.1B
Licenses	$0.1B

Business quality (Weak): The provided quarter revenue is listed as 0.0B while segment revenue candidates are nonzero, so figures appear rounded or inconsistent. Otherwise, the segment and operating metric labels are clear, and the clinical focus is directly supported by the company description.

Bull case

Multiple clinical programs built around an off-the-shelf T-cell approach: The company is developing tabelecleucel for Phase 3 in EBV-driven post-transplant lymphoproliferative disease and also for hematologic and solid tumors, and it is developing next-generation CAR T immunotherapies (ATA2271 and ATA3271).
Evidence of monetization categories: The provided segment revenue candidates include Commercialization Revenue and License and Collaboration Revenue, indicating some contribution from both treated patients and partnerships.

Bear case

Development and approval uncertainty: Key programs are still described in the context of clinical trial development, including Phase 3 for tabelecleucel, so outcomes and regulatory timing can materially affect future revenue scale.
Loss-making economics (at least in the latest provided quarter): For the latest provided period (2026-03-31), operating margin is listed as -652.9, which reflects substantial operating losses.

Valuation — source: SEC EDGAR (first-party)
Price	$9.77
Market Cap	$98.07M
Price / Sales	19.17
FCF Yield	-46.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$120.77M
Net Margin	27.1%
Revenue Growth (YoY)	-6.3%
EPS Growth (YoY)	-122.9%
FCF Growth (YoY)	-26.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	-127.41 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock Fund Advisors ($15.78M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Anhco Nguyen
Employees	153
Country	US
IPO Date	2014-10-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.